Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Goldman Sachs Initiates Coverage On RAPT Therapeutics with Buy Rating, Announces Price Target of $27

Goldman Sachs Initiates Coverage On RAPT Therapeutics with Buy Rating, Announces Price Target of $27

Goldman Sachs analyst Corinne Jenkins initiates coverage on RAPT Therapeutics (NASDAQ:RAPT) with a Buy rating and announces Price Target of $27.

December 1, 2022

1 minute read

Goldman Sachs analyst Corinne Jenkins initiates coverage on RAPT Therapeutics (NASDAQ:RAPT) with a Buy rating and announces Price Target of $27.

Greenlane Launches Its Latest Cooling Vaporizer: The ARTIQ By DaVinci

June 14, 8:09 AM

Greenland Holdings, Inc. (NASDAQ: GNLN), announced the launch of the DaVinci ARTIQ, the newest in a line of premium portable vaporizers.

May 3, 2:56 PM

Akili Inc (NASDAQ: AKLI) announced the topline results of the STARS-ADHD-Adult trial evaluating EndeavorRx (AKL-T01) in adults with attention

August 31, 10:48 AM

What is a Value Stock? A value stock traditionally has a lower price when compared to stock prices…

November 16, 12:08 PM

-Reuters